Cancers Treated:
Research Interests:
- Novel therapies for breast and urothelial cancer
Positions
Roswell Park Comprehensive Cancer Center
- Professor of Oncology
- Chief, Breast Medicine
- Department of Medicine
-
Hematology/Medical Oncology Fellowship Program Director
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
- Professor of Medicine
- Hematology/Medical Oncology Fellowship Program Director
Background
Education and Training
- MD - University of Pittsburgh, Pittsburgh, PA
Residency
- University of Minnesota, Minneapolis, MN
Fellowship
- University of Minnesota, Minneapolis, MN
Board Certification
- Internal Medicine, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
Honors & Awards
- 2005-2023 - America’s Top Doctors
- 2018 - Susan G. Komen Hope Award for Upstate New York
Clinical Trials
Featured on CancerTalk
Showing all3 of 12 CollapseView all
Publications
Alaklabi S, Roy AM, Attwood K, George A, O'Connor T, Early A, Levine EG, Gandhi S. Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience. Front Oncol. 2022 Oct 20;12:1012391. doi: 10.3389/fonc.2022.1012391. PMID: 36338738; PMCID: PMC9631302.
Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood KM, Groman A, Williams l, Tarquini ML, Wallace PK, Soh KT, Minderman H, Mcguire O, O’Connor TL, Early AP, Levine EG, Kalinski P (2022) Systemic IFN-a/TLR3-Ligand Combination Reprograms Local Microenvironments of Breast Cancer Lesions for Selective CTL Influx. Journal for ImmunoTherapy of Cancer 2023;11:e007381. doi: 10.1136/jitc-2023-007381
Ademuyiwa FO, Northfelt DW, O'Connor T, Levine E, Luo J, Tao Y, Hoog J, Laury ML, Summa T, Hammerschmidt T, Guo Z, Frith A, Weilbaecher K, Opyrchal M, Aft R, Clifton K, Suresh R, Bagegni N, Hagemann IS, Iglesia MD, Ma CX. A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). NPJ Breast Cancer. 2023 Jan 6;9(1):1. doi: 10.1038/s41523-022-00504-z. PMID: 36609389; PMCID: PMC9822956.
Abraham A, Barcenas CH, Bleicher RJ, Cohen AL, Javid SH, Levine EG, Lin NU, Moy B, Niland JC, Wolff AC, Hassett MJ, Asad S, Stover DG. Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study. Breast. 2023 Feb;67:89-93. doi: 10.1016/j.breast.2023.01.004. Epub 2023 Jan 17. PMID: 36681001.
Witkiewicz AK, Schultz E, Wang J, Hamilton D, Levine E, O'Connor T, Knudsen ES. Determinants of response to CDK4/6 inhibitors in the real-world setting. NPJ Precis Oncol. 2023 Sep 13;7(1):90. doi: 10.1038/s41698-023-00438-0. PMID: 37704753; PMCID: PMC10499925.
Witkiewicz AK, Wang J, Schultz E, O’Connor TN, O’Connor T, Levine E, Knudsen E. Developing Algorithms to Predict the Duration of Response to CDK 4/6 Inhibitor-Based Therapy in Metastatic HR+/HER2- Breast Cancer. submitted